Teva gets tentative FDA OK for generic Norvasc

03/28/2005 | NYTimes.com

Teva Pharmaceutical received tentative FDA approval for marketing its generic version of Pfizer's Norvasc for treating hypertension and angina, worth $2.4 billion in annual sales for Pfizer. Teva said it expects final agency approval once Pfizer's patent on the drug expires in September 2007.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA